Newsroom

LOTTE BIOLOGICS (CEO James Park) announced on May 30th that it will showcase its differentiated competitiveness as a global CDMO by consecutively participating in international bio events to be held in Incheon, Korea and Boston, USA this June.

Starting with the World ADC Asia Summit, which will take place in Incheon from June 10 to 12, LOTTE BIOLOGICS will also participate in the 2025 BIO International Convention (hereinafter referred to as “BIO USA”), to be held in Boston, USA from June 16 to 19 (local time).

World ADC Asia is Asia’s leading antibody-drug conjugate (ADC) event, now in its fourth year. It brings together a wide range of participants interested in ADCs to discuss the latest research and technological trends in development and manufacturing. At this event, LOTTE BIOLOGICS plans to explore new business partnerships with potential clients in the Asia-Pacific region and further solidify its position as a global CDMO.

In January, LOTTE BIOLOGICS unveiled its proprietary and innovative ADC platform, SoluFlex Link, at the J.P. Morgan Healthcare Conference. In April, the company signed a manufacturing agreement with a bio firm in Asia for the production of clinical trial materials for an ADC candidate, further accelerating its market expansion.

BIO USA is the world’s largest bio-pharmaceutical exhibition, organized annually by the Biotechnology Innovation Organization (BIO). It serves as a platform where stakeholders from across the global bio and pharmaceutical industries gather to discuss partnerships. LOTTE BIOLOGICS will be participating for the fourth consecutive year since 2022.

At its dedicated exhibition booth, LOTTE BIOLOGICS will provide company introductions for visitors, while a “private meeting room” located at the back of the booth will be used both for in-depth partnering discussions with global pharmaceutical companies and biotech ventures, as well as for meetings with general visitors.

LOTTE BIOLOGICS will present the blueprint for its commercial operations, including the full-scale launch of ADC production at its Syracuse Bio Campus and the scheduled commercial operation of Plant 1 at the Songdo Bio Campus in 2027. The company plans to highlight its differentiated strengths as a global CDMO by promoting the geographic advantage of its “dual site” model, which enables flexible and timely responses to client needs, as well as emphasizing its one-stop ADC services and the quality competitiveness of the newly constructed Songdo Bio Campus.

A LOTTE BIOLOGICS representative stated, “We will present concrete business strategies based on the synergy between the Syracuse and Songdo Bio Campuses to a wide range of potential global clients,” and added, “Through active partnering at international bio events, we will continue to strengthen LOTTE BIOLOGICS’ global competitiveness.”

End.